Navigation Links
Notal Vision chooses TrialStat's ClinicalAnalytics 4.0 for age-related macular degeneration (AMD) device trial
Date:12/13/2007

ClinicalAnalytics 4.0 Links Images of Study Participant Eyes with Wet AMD

to Electronic Case Report Forms (eCRFs)

OTTAWA, Dec. 13 /PRNewswire/ - TrialStat Corporation, the industry's first clinical data solutions on demand company, today expanded its international customer base with news that Notal Vision(TM), an Israeli-based medical device company specializing in the early detection of AMD, has selected ClinicalAnalytics 4.0(TM) (CA) for a Phase II device trial that will occur in Israel and the United States. Notal Vision's flagship product is The Foresee Preferential Hyperacuity Perimeter (Foresee PHP(TM)), which is a non-invasive diagnostic tool for the detection and monitoring of wet AMD. Wet AMD is the most severe form of AMD. AMD affects approximately 50 million people worldwide.

The medical device company selected TrialStat for its on demand flexibility, the ability to attach images to eCRFs and import data from Notal Vision's medical devices. A key part of the trial requires independent ophthalmologists to review Foresee PHP's ability to evaluate the progression of wet AMD in study participants. CA 4.0 allows the study's researchers to easily attach images of participant eyes to an eCRF to enable ophthalmologists to view them and enter data for analysis in one step, further speeding the collection and management of study data. In addition, patient data from Foresee PHP can be imported to CA 4.0 in XML format for review, allowing for optimal flexibility in capturing trial data.

"TrialStat was unique among EDC vendors in their capacity to provide an integrated image attachment solution that allowed us to quickly deploy our study," said Miri Sani, Vice President of Clinical and Regulatory Affairs, Notal Vision. "Our ability to use a flexible on demand EDC solution that easily integrated with our management of trial data underscores CA's robust scalability and innovative image-based tools."

"Easily attaching images to eCRFs provides our customers with the ability to more effectively and efficiently capture and analyze data," said Jonathan Barker, President and CEO, TrialStat. "With Notal Vision, we provided an innovative approach to using images so that researchers can intuitively enter data to accelerate the management and completion of their study."

ABOUT TRIALSTAT

---------------

TrialStat Corporation provides innovative clinical data solutions on demand that optimize the collection and management of research to enable customers to accelerate the commercialization of new life science products. CA 4.0 is a robust and scaleable Web-based EDC on demand platform used by leading biopharma organizations. SRS 4.0(TM) automates systematic reviews using real-time collaboration and management tools, while ESRNexus(TM) (http://www.esrnexus.com) is the most comprehensive and free Web-based search engine for evidence-based reference literature. More information about TrialStat is available at http://www.trialstat.com.

ABOUT NOTAL VISION

------------------

Notal Vision was founded in 2000 by medical professionals from Israel's leading medical centers. The Company has assembled a team of ophthalmologists that have AMD expertise and business experience, R&D specialists, engineers, software engineers, business developers and researchers. Currently, there are 25 full-time employees, of them 4 MDs and 4 PhDs. In addition, Notal has recruited a scientific advisory board that includes leading retinal specialists from around the world. The company is developing the first comprehensive diagnostic solution for the early detection and monitoring of Age-Related Macular Degeneration (AMD), the leading cause of blindness in the western world today. To address the growing need for early detection of wet AMD and for the continuous monitoring of patients with dry AMD, Notal Vision(TM) has developed the patented Preferential Hyperacuity Perimetery - Foresee PHP platform, designed to detect and monitor the progression of the disease in a non-invasive manner in the clinic or through frequent use at home.

ClinicalAnalytics 4.0, SRS 4.0 and ESRNexus are registered trademarks of

TrialStat Corporation.

Notal Vision and The Foresee Preferential Hyperacuity (Perimeter Foresee

PHP(TM)) is a trademark of Notal Vision.


'/>"/>
SOURCE TrialStat
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
2. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
3. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
4. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
5. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
6. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
7. Environmental Tectonics Corporations BioMedical Division Announces New Contract
8. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
9. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
10. H&V Introduces HVision Technology Platform to Accelerate Development of Breakthrough Products
11. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... Windsor, Conn. (PRWEB) , ... March 01, 2017 ... ... Morris Group, Inc. will hold its annual technology show and open house, Southern ... display CNC machinery from Okuma, Tsugami, Hardinge Group and Chiron and perform live ...
(Date:2/28/2017)... , ... February 28, 2017 , ... Surface Plasmon Resonance ... is an optical phenomenon that is sensitive to changes in the dielectric properties of ... affected by changes in refractive index occurring up to 300 nm above the metal ...
(Date:2/28/2017)... Calif. , Feb. 28, 2017   Sienna ... and aesthetics company, is pleased to announce that ... advisor to Sienna,s CEO and Board of Directors. Dr. ... and chief executive officer of Allergan for 17 years. ... return to dermatology and aesthetics. "I look ...
(Date:2/28/2017)... Mass. and REYKJAVIK, Iceland , ... WuXi AppTec group company and the contract genomics organization ... operating officer Hannes Smarason has been appointed as the company,s ... John Long and Alex Fowkes have been ... "WuXi NextCODE is executing on its vision to ...
Breaking Biology Technology:
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
(Date:1/30/2017)... Jan. 30, 2017   Invitae Corporation (NYSE: ... genetic information companies, today announced that it will report ... provide 2017 guidance on Monday, February 13, 2017, and ... day at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... will briefly review financial results, guidance, and recent developments ...
Breaking Biology News(10 mins):